Ophthalmology 360
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Photo Contest
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
2nd Annual Photo Contest - Enter Here!
Ophthalmology 360
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Photo Contest
    • Industry Council
    • Advisory Board
Home > Geographic Atrophy > Pachychoroid GA progresses slower, shows unique demographic features, study finds
  • Geographic Atrophy

Pachychoroid GA progresses slower, shows unique demographic features, study finds

Kelsey Moroz

Pachychoroid geographic atrophy (GA) and conventional GA exhibit distinct clinical characteristics and progression rates, according to a study that found pachychoroid GA is associated with younger age, male predominance, better visual acuity, thicker choroids, smaller GA areas, and significantly slower progression rates compared to conventional GA.

This retrospective, multicenter observational study conducted across university hospitals in Japan included 173 eyes (38 eyes with pachychoroid GA and 135 eyes with conventional GA). A subset of 101 eyes was followed over time to assess GA progression rates. Pachychoroid GA was identified based on the presence of pachychoroid features and the absence of drusen.

Key Findings:

  • Demographics: The pachychoroid GA group was significantly younger, with a mean age of 70.3 years compared to 78.7 years in the conventional GA group. This group also had a higher male predominance (89.5% vs 55.6%).
  • Visual Acuity and Choroidal Thickness: Patients with pachychoroid GA exhibited better visual acuity (0.15 vs 0.40 in logarithm of the minimum angle of resolution) and thicker choroids (312.4 µm vs 161.6 µm).
  • GA Characteristics: The pachychoroid GA group had a higher incidence of unifocal GA (94.7% vs 49.6%) and smaller GA areas (0.59 mm² vs 3.76 mm²).

In the follow-up group, the mean GA progression rate was significantly lower for pachychoroid GA (0.11 mm/year) compared to conventional GA (0.27 mm/year). This slower progression rate persisted even after adjusting for age and baseline GA area.

Reference
Sato Y, Ueda-Arakawa N, Takahashi A, et al. Clinical Characteristics and Progression of Pachychoroid and Conventional Geographic Atrophy. Ophthalmol Sci. 2024;4(5):100528. doi: 10.1016/j.xops.2024.100528. PMID: 38827489; PMCID: PMC11143896.

This content is independent editorial sponsored by Astellas. Astellas had no input in the development of this content.

Share

Related Content

  • Geographic Atrophy

Geographic atrophy linked to vision loss, higher healthcare costs, and fall risk

  • Geographic Atrophy

Spotlight on IZERVAY®

  • Geographic Atrophy

Two-year GATHER2 data show sustained GA growth reduction with avacincaptad pegol

  • Conference Roundup

Floretina 2025: study shows reduced treatment burden with EYP-1901 for neovascular AMD

3 Mins Watch
  • Geographic Atrophy

Over half of patients with dry AMD developed advanced disease in long-term analysis

  • Geographic Atrophy

Monthly avacincaptad pegol reduces geographic atrophy lesion growth for up to 3.5 years

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Ophthalmology 360

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon